Clinical trials: Diabetic Complication
Kidney Disease, Chronic
A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function…
- Trial name
- NCT05182840
- Testing
- BI 690517, Empagliflozin
- Where
- 203 sites in United States, Argentina and 27 more
- Volunteers
- 714 people
- Sponsor
- Boehringer Ingelheim
Microalbuminuria
Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria
The objective of the study is to assess the effect of standard versus aggressive inhibition of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA) on; a)progression of microalbuminuria…
- Trial name
- END-IT (NCT00907374)
- Testing
- benazepril
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Charles Drew University of Medicine and Science
Diabetic Neuropathy
A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of Tapentadol (CG5503) extended release (ER) (base) compared to placebo in patients with moderate to severe pain from diabetic…
- Trial name
- NCT00455520
- Testing
- CG5503
- Volunteers
- 395 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetic Macular Edema
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) on the best corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS)…
- Trial name
- VISTA DME (NCT01363440)
- Testing
- Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation
- Where
- 51 sites in United States
- Volunteers
- 466 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Retinopathy, Posterior Vitreous Detachment
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to…
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Trial name
- CIRCLE (NCT02681809)
- Testing
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg
- Where
- 38 sites in United States, Czechia and 7 more
- Volunteers
- 48 people
- Sponsor
- ThromboGenics
Diabetic Foot Ulcers
Negative Pressure Wound Therapy as a Drug Delivery System
The investigators plan a randomized clinical trial of 150 patients with infected diabetes-related lower extremity wounds to compare the clinical and economic effectiveness of negative pressure wound therapy with continuous…
- Trial name
- NCT02463487
- Testing
- Cardinal Pro +Simultaneous Irrigation (NPWTi), Cardinal Pro (NPWT) Therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetic Neuropathy, Pain
Spinal Cord Stimulation for Painful Diabetic Neuropathy
The purpose of this study is to evaluate Spinal Cord Stimulation (SCS) therapy in individuals who suffer from painful diabetic peripheral neuropathy.
- Conditions
- Diabetic Neuropathy, Pain, Peripheral Neuropathy
- Trial name
- DPN (NCT00487981)
- Testing
- Precision Spinal Cord Stimulation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Boston Scientific Corporation
Diabetic Foot Ulcer
Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers
The purpose of the current Study is to determine the safety and effectiveness of Galnobax® plus Standard of Care versus only Standard of Care, in treating Diabetic Foot Ulcers (DFU).
- Trial name
- NCT03998436
- Testing
- Esmolol Hydrochloride, Only Standard of Care, Vehicle Gel
- Where
- 14 sites in India
- Volunteers
- 176 people
- Sponsor
- Novalead Pharma Private Limited
Diabetic Neuropathies
A Long-term Study for the Treatment of Painful Diabetic Neuropathy
The purpose of the study is to investigate safety and efficacy of duloxetine for patients with painful diabetic neuropathy at long-term use.
- Trial name
- NCT00641719
- Testing
- Duloxetine hydrochloride
- Where
- 25 sites in Japan
- Volunteers
- 258 people
- Sponsor
- Eli Lilly and Company
SLE, Lupus Nephritis
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
This study aims to assess sodium glucose linked transoprter inhibitors(SGT2i) role in regression of ongoing kidney and cardiac diseases among lupus nephritis patient either diabetic or non-diabetic under different…
- Conditions
- SLE, Lupus Nephritis, SGLT2 Inhibitors
- Trial name
- NCT05748925
- Testing
- dapagliflozin
- Where
- Egypt
- Volunteers
- 84 people
- Sponsor
- Mansoura University
Diabetic Foot Ulcer, Ulcer Foot
Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available treatments for diabetic foot wounds.
- Conditions
- Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
- Trial name
- NCT06403605
- Testing
- Mirragen Advanced Wound Matrix, Fibracol
- Where
- 15 sites in United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- ETS Wound Care, LLC
Peripheral Arterial Disease, Diabetic Foot
Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy and safety of intramuscular administration of human placenta-derived cells (PDA-002) in subjects with…
- Trial name
- DFU-002 (NCT02264288)
- Testing
- PDA-002
- Where
- 45 sites in United States
- Volunteers
- 159 people
- Sponsor
- Celularity Incorporated
Diabetic Foot Ulcer
Improving DFU Outcomes: Early Detection of Foot Ulcers Using Novel Technology
The investigator team will study the adherence of the participant cohort to a non significant risk device over a six month period.
- Trial name
- DFUMAT (NCT05968924)
- Testing
- Podimetrics SmartMat
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Chronic Renal Impairment, Diabetes Mellitus
Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients
The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with moderate-to-severe…
- Trial name
- RECARE (NCT00782639)
- Testing
- Iopamidol injection 76%, iodixanol
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Bracco Diagnostics, Inc
Diabetic Foot Ulcers, Wound
Topical Oxygen Therapy for Diabetic Wounds
This is a pilot study which is intended to collect data to calculate an adequate sample size for a larger registered clinical trial.
- Trial name
- NCT02313428
- Testing
- Topical Oxygen Chamber for Extremities
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Indiana University
Type2 Diabetes Mellitus, Complications
Morbidity in Newly Diagnosed type2 Diabetes in Adults
It is a prospective,observational, cohort study The main purpose of the study is to assess the prevalence of diabetic chronic complications in newly diagnosed type 2 diabetics in suburban area of Algiers.
- Trial name
- MORNDIAB (NCT02002091)
- Testing
- no specific treatment
- Where
- Algeria
- Volunteers
- 327 people
- Sponsor
- University of Algiers
Diabetic Neuropathy, Painful
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to…
- Trial name
- NCT00385671
- Testing
- duloxetine hydrochloride, pregabalin, gabapentin
- Where
- 9 sites in United States, Germany
- Volunteers
- 407 people
- Sponsor
- Eli Lilly and Company
Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
A frequent complication in the management of diabetic ketoacidosis (DKA) in children with type 1 diabetes is rebound hyperglycemia (blood glucose over 180 mg/dL) which increases the risk of re-developing DKA and can lengthen the…
- Trial name
- NCT03107208
- Testing
- Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the safety profile of orally administered tapentadol ER dosages of 100 to 250 mg twice daily in patients with chronic, painful diabetic peripheral neuropathy (DPN) over long-term exposure…
- Trial name
- NCT01063868
- Testing
- Tapentadol extended release (ER), Oxycodone controlled release (CR)
- Where
- 23 sites in United States
- Volunteers
- 47 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.